Evotec AG
Neuroscience/Drug Discovery Company
Website
www.evotec.com
Contact Name
Dr. Werner Lanthaler
Company Position
Chief Executive Officer
Contact Email
info@evotec.com
Contact Address
Evotec AG
Schnackenburgalle 114
22525 Hamburg
Germany
Contact Phone
+49 40 560 81286
Latest News
9th March 2009
Evotec AG and Roche have announced that they have entered into an agreement for Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds US$300 million.
Read this article
More News
2nd September 2008
Evotec AG today announced that a third milestone has been successfully achieved in their collaboration with Boehringer Ingelheim.
Read this article
5th May 2008
Evotec AG announced that the merger has been successfully completed and that Renovis, Inc. is a wholly owned subsidiary of Evotec as of May 5, 2008.
Read this article
16th October 2007
Evotec AG has announced positive top-line results from its second phase II trial of EVT 201.
Read this article
Evotec is a leader in the discovery and development of the next generation of novel small molecule drugs both through its own discovery programmes and through contract research partnerships. In its own discovery programmes, the Company specialises in finding new treatments for diseases of the central nervous system (CNS), which were expanded in March 2005 through the acquisition of Evotec Neurosciences. The Company now has a number of products in late stage pre-clinical and clinical development, including a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and a GABA A receptor modulator for insomnia.
In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative solutions from drug target to clinic through an unmatched range of integrated capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
Evotec AG acquired Evotec Neurosciences in 2005 and is quoted on the Deutsche Börse Stock Exchange. (EVT.DE)
